Efficacy of Nalfurafine for Chronic Kidney Disease-Associated Pruritus in Twice-Weekly Hemodialysis Patients: a Randomized Controlled Trial

This study evaluates the efficacy and safety of nalfurafine as a treatment for chronickidney disease‐associated pruritus (CKD‐aP) in patients undergoing maintenancehemodialysis twice weekly.Pruritus (severe itching) is a common and distressing symptom in patients with end‐stagerenal disease receiving hemodialysis, significantly impairing their quality of life.Nalfurafine is a selective kappa‐opioid receptor agonist designed to reduce itching.The main objective of this clinical trial is to evaluate whether nalfurafine effectivelyreduces itch intensity and improves symptom control compared to control, while monitoringfor any adverse effects.